Skip to main content
Annals of Translational Medicine logoLink to Annals of Translational Medicine
. 2023 Jul 19;11(10):378. doi: 10.21037/atm-2023-15

Erratum to atractylodin may induce ferroptosis of human hepatocellular carcinoma cells

Editorial Office1
PMCID: PMC10477627  PMID: 37675338

This article (1) titled “Atractylodin may induce ferroptosis of human hepatocellular carcinoma cells” (doi: 10.21037/atm-21-4386), unfortunately contains errors in Figure 3 and the Reagents and Antibodies section of the main text.

The pictures of Figure 3A and 3C overlapped and should be corrected. The corrected Figure 3 is presented below.

Corrected Figure 3:

graphic file with name atm-11-10-378-fig1.jpg

In the Reagents and Antibodies section, part of the first sentence should be changed from “Atractylin (C13H10O), purity ≥99%, relative molecular weight: GPX4 polyclonal antibody (#14432-1-AP), ACSL4 monoclonal antibody (#666171-IG), CD71, GPX4 polyclonal antibody (#14432-1-AP)” to “Atractylotin (C13H10O), purity ≥99%, GPX4 polyclonal antibody (#14432-1-AP), Beta Actin Recombinant antibody (#81115-1-RR)”.

The authors apologize for the oversight.

Click here to view the updated version of the article.

References

  • 1.He Y, Fang D, Liang T, et al. Atractylodin may induce ferroptosis of human hepatocellular carcinoma cells. Ann Transl Med 2021;9:1535. 10.21037/atm-21-4386 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of Translational Medicine are provided here courtesy of AME Publications

RESOURCES